期刊文献+

Red cell distribution width/platelet ratio estimates the 3-year risk of decompensation in Metabolic Dysfunction-Associated Steatotic Liver Disease-induced cirrhosis

下载PDF
导出
摘要 BACKGROUND For compensated advanced chronic liver disease(cACLD)patients,the first decompensation represents a dramatically worsening prognostic event.Based on the first decompensation event(DE),the transition to decompensated advanced chronic liver disease(dACLD)can occur through two modalities referred to as acute decompensation(AD)and non-AD(NAD),respectively.Clinically Significant Portal Hypertension(CSPH)is considered the strongest predictor of decompensation in these patients.However,due to its invasiveness and costs,CSPH is almost never evaluated in clinical practice.Therefore,recognizing noninvasively predicting tools still have more appeal across healthcare systems.The red cell distribution width to platelet ratio(RPR)has been reported to be an indicator of hepatic fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease(MASLD).However,its predictive role for the decompensation has never been explored.AIM In this observational study,we investigated the clinical usage of RPR in predicting DEs in MASLD-related cACLD patients.METHODS Fourty controls and 150 MASLD-cACLD patients were consecutively enrolled and followed up(FUP)semiannually for 3 years.At baseline,biochemical,clinical,and Liver Stiffness Measurement(LSM),Child-Pugh(CP),Model for End-Stage Liver Disease(MELD),aspartate aminotransferase/platelet count ratio index(APRI),Fibrosis-4(FIB-4),Albumin-Bilirubin(ALBI),ALBI-FIB-4,and RPR were collected.During FUP,DEs(timing and modaities)were recorded.CSPH was assessed at the baseline and on DE occurrence according to the available Clinical Practice Guidelines.RESULTS Of 150 MASLD-related cACLD patients,43(28.6%)progressed to dACLD at a median time of 28.9 months(29 NAD and 14 AD).Baseline RPR values were significantly higher in cACLD in comparison to controls,as well as MELD,CP,APRI,FIB-4,ALBI,ALBI-FIB-4,and LSM in dACLD-progressing compared to cACLD individuals[all P<0.0001,except for FIB-4(P:0.007)and ALBI(P:0.011)].Receiving operator curve analysis revealed RPR>0.472 and>0.894 as the best cut-offs in the prediction respectively of 3-year first DE,as well as its superiority compared to the other non-invasive tools examined.RPR(P:0.02)and the presence of baseline-CSPH(P:0.04)were significantly and independently associated with the DE.Patients presenting baseline-CSPH and RPR>0.472 showed higher risk of decompensation(P:0.0023).CONCLUSION Altogether these findings suggest the RPR as a valid and potentially applicable non-invasive tool in the prediction of timing and modalities of decompensation in MASLD-related cACLD patients.
出处 《World Journal of Gastroenterology》 SCIE CAS 2024年第7期685-704,共20页 世界胃肠病学杂志(英文版)
  • 相关文献

参考文献2

二级参考文献21

  • 1Mustafa Cengiz,Burcu Aslan Candir,Güldal Yilmaz,Gülen Akyol,Seren Ozenirler.Is increased red cell distribution width an indicating marker of nonalcoholic steatohepatitis and fibrotic stage?[J].World Journal of Gastroenterology,2013,19(42):7412-7418. 被引量:8
  • 2Simona Bota,Harald Herkner,Ioan Sporea,Petra Salzl,Roxana Sirli,Adriana M. Neghina,Markus Peck‐Radosavljevic.Meta‐analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis[J].Liver Int.2013(8)
  • 3Sudhakar Kundapur Venkatesh,Gang Wang,Seng Gee Lim,Aileen Wee.Magnetic resonance elastography for the detection and staging of liver fibrosis in chronic hepatitis B[J].European Radiology.2014(1)
  • 4E. L. Haseltine,M. S. Penney,S. George,T. L. Kieffer.Successful treatment with telaprevir‐based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis[J]. J Viral Hepat . 2015 (9)
  • 5Matthew T. Heller,Mitchell E. Tublin.The Role of Ultrasonography in the Evaluation of Diffuse Liver Disease[J]. Radiologic Clinics of North America . 2014 (6)
  • 6J. Boursier,C. Brochard,S. Bertrais,S. Michalak,Y. Gallois,I. Fouchard‐Hubert,F. Oberti,M.‐C. Rousselet,P. Calès.Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver‐prognosis in chronic hepatitis C[J]. Aliment Pharmacol Ther . 2014 (2)
  • 7Olav A. Gressner,Chunfang Gao.Monitoring fibrogenic progression in the liver[J]. Clinica Chimica Acta . 2014
  • 8Isabel Rauscher,Matthias Eiber,Carl Ganter,Petros Martirosian,Wajima Safi,Andreas Umgelter,Ernst J. Rummeny,Konstantin Holzapfel.Evaluation of T 1ρ as a potential MR biomarker for liver cirrhosis: Comparison of healthy control subjects and patients with liver cirrhosis[J]. European Journal of Radiology . 2014
  • 9Rajarshi Banerjee,Michael Pavlides,Elizabeth M. Tunnicliffe,Stefan K. Piechnik,Nikita Sarania,Rachel Philips,Jane D. Collier,Jonathan C. Booth,Jurgen E. Schneider,Lai Mun Wang,David W. Delaney,Ken A. Fleming,Matthew D. Robson,Eleanor Barnes,Stefan Neubauer.Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease[J]. Journal of Hepatology . 2014 (1)
  • 10Vasilios Papastergiou,Maria Stampori,Phillipos Lisgos,Crisostomos Pselas,Kleopatra Prodromidou,Stylianos Karatapanis.Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study[J]. European Journal of Gastroenterology & Hepatology . 2013 (7)

共引文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部